The D-Nav Insulin Guidance device was developed by an American-based company, Hygieia, in hopes, that people with diabetes can reduce the number of times they need to visit the doctor’s office. This device is the brain child of Dr. Eran Bashan and Dr. Israel Hodish, and it is also known as “the doctor in your pocket”.
No larger than a typical cell phone, this device helps patients easily regulate their insulin. This can certainly be a benefit to the thousands of individuals that diabetes affects.
Due to the rising cost of healthcare, patients are encouraged to seek treatment for a special illness from their general practitioner, instead of getting proper treatment from more costly specialized medical professionals. Basically, many people will forfeit going to the doctor all together, and not be treated for their disease, especially diabetes.
Not only does the D-Nav system monitor blood glucose levels, but it calculates your insulin dosage based on those numbers, that are pre-programmed by a health care professional.
To simplify the explanation of how the D-Nav Insulin Guide System (DIGS) works, consider the global positing system (GPS) that guides you to your destination. Similar to a GPS unit, the DIGS system automatically maps out insulin dosage, so you don’t travel too far off course. Remember, a GPS tells you what to do next, but the decision to act on the instructions are up to you.
It has been shown, through extensive studies, that insulin therapy is much more effective when the dosage is adjusted frequently, based on the patterns of blood sugar levels of an individual. The D-Nav system works like a traditional finger prick, to retrieve a drop of blood to test, but when combined with the new technology, it allows a patient to adjust their insulin dosage immediately, without waiting months for their next doctor’s visit. In turn, this makes the treatment for diabetes more effective, and any complications associated with diabetes (such as blindness and neuropathy) reduced.
In just once study conducted at the Ulster Hospital, more than 150 patients (with both Type One and Type Two Diabetes) were effectively treated using the D-NAV Insulin Guidance Device.
Many positive testimonials, by diabetic patients that were part of the clinical trial, include individuals who stated, that they were able to make slight adjustments to their insulin levels immediately. For instance, if their BGL (blood glucose levels) were slightly higher than they should be – 8.2 instead of 7 – then action could be taken quickly, and insulin adjustment can be done immediately. Before the D-Nav system, insulin was administered based on the later number, and basically it means that the body was not properly treated, and the dosage was lower than it should have been.
As of the writing of this article, D-Nav has not been approved by the United States Food and Drug Administration (FDA).